Axial Spondyloarthritis: Clinical Characteristics, Epidemiology, and General Approaches to Management (2023)


Axial spondyloarthritis (axSpA) is a chronic inflammatory condition that predominantly affects the sacroiliac joints and spine. It is a type of spondyloarthritis (SpA) that refers to a group of inter-related conditions including psoriatic arthritis (PsA), reactive arthritis, and arthritis associated with inflammatory bowel disease (IBD).1 Ankylosing spondylitis (AS) was the prototype SpA condition, diagnosed when characteristic changes of sacroiliitis are seen on an X-ray of the pelvis in conjunction with clinical criteria.2 It has been increasingly recognised that the characteristic radiographic changes of AS could take many years to develop, thus excluding a large group of people with suggestive symptoms, but normal X-rays. This led to the development of the Assessment of SpondyloArthritis international Society (ASAS) criteria in 2009, which recognised a radiographic stage broadly similar to AS, as well as a non-radiographic stage (nr-axSpA).3 This allowed individuals with earlier or less severe disease, who had suggestive clinical features and sacroiliitis on magnetic resonance imaging, to be classified as axSpA.


AxSpA typically occurs in the third decade of life, and almost exclusively before 45 years of age. Historically, AS was considered to be a male-dominated disease, with early literature reporting ratios of up to 10:1. However, more recent estimates put that ratio at closer to 3:1, with virtually no difference seen in the distribution of nr-axSpA between men and women.4

The major histocompatibility complex 1 human leukocyte antigen (HLA)-B27 allele is strongly associated with axSpA, and is found in 74–89% of affected individuals.5 The prevalence of axSpA is typically greater in populations with a higher background prevalence of HLA-B27.4 In Europe, the prevalence of HLA-B27 varies from 2% to 25% and is highest in Scandinavian countries.6 In contrast, HLA-B27 is rare in Japan and Arab countries, and almost non-existent in some populations such as indigenous tribes of South America.6 The Pawaia tribe in Papua New Guinea has the highest prevalence of HLA-B27 worldwide, with 53% of people affected.7

In 2016, Stolwijk et al.8 systematically estimated the global prevalence of axSpA between 0.36% and 0.70% and AS between 0.20% and 0.25%. The lowest prevalence was in Southeast Asia with a pooled prevalence of 0.2% and the highest in the northern Arctic communities. The native Eskimo (Inuit) population demonstrated a strikingly high prevalence of SpA of 2.5%, with the prevalence of HLA-B27 also high, affecting up to 40% of the study population.9

However, in reality it is difficult to know the true prevalence of axSpA because of a lack of population studies and a continued under-recognition and underdiagnosis of axSpA. In addition, delay to diagnosis has been a longstanding challenge in the management of axSpA, with mean delays of approximately 7 years reported in a large meta-analysis of 23,883 individuals.10 Long delays to diagnosis are associated with a number of worse outcomes in axSpA, such as more active disease, greater chance of disability, and increased healthcare costs.11 The delay to diagnosis is more common in women than men.10 Women are less likely to report typical inflammatory back-pain symptoms, and more likely to report widespread pain; misdiagnoses such as fibromyalgia (FM) are more commonly made in the female population,12 which may also exacerbate diagnostic delay. A negative HLA-B27 also appears to be associated with diagnostic delay.13 If undiagnosed or under-treated, axSpA may lead to continuous pain, stiffness, and fatigue, and may ultimately lead to a reduction in quality of life (QoL).


Most pathogenesis studies to date have focused on AS rather than axSpA. It appears to develop through complex interactions between genetic background and environmental factors. Studies performed on monozygotic twins and familial aggregation studies suggest that AS has a heritability of above 90%.14,15 HLA-B27 positivity is also strongly linked with AS, occurring in only about 5% of the general population, but more than 90% of individuals with AS.16 Exactly how HLA-B27 predisposes to AS is not yet fully understood, but several hypotheses have been put forward:17

  1. Arthritogenic peptide hypothesis: the specific sequence of amino acids found in the peptide-binding groove of HLA-B27 might bind a peptide which elicits a cytotoxic T-cell response cross-reactive with a B27/self-peptide combination, i.e., molecular mimicry.16
  2. HLA-B27 misfolding hypothesis: it is thought that the specific sequence of amino acids in the peptide-binding groove causes a propensity for HLA-B27 to misfold in the endoplasmic reticulum, leading to a pro-inflammatory stress response; however, evidence to date is largely limited to rat studies.18
  3. Cell-surface B27 free heavy chain expression and immune recognition hypothesis: HLA-B27 tends to form homodimers, which bind to free heavy chains expressed on the cell surface, thus triggering a pro-inflammatory process.16

However, despite this strong association, HLA-B27 contributes only 33% of the total heritability of AS.16 Genome-wide association studies have additionally detected several genes associated with AS.19 Barrier damage to the skin or gut surfaces may also be relevant to pathogenesis.20 Microbial infection appears to act as a triggering factor.21


Axial Symptoms

Patients typically present with inflammatory back pain (IBP), characterised by an insidious onset of lower back and alternating buttock pain that worsens with inactivity and improves with exercise and non-steroidal anti-inflammatory drugs (NSAID). Patients may report waking at night with lower back pain, particularly in the latter stages of sleep. IBP is also associated with morning stiffness that usually lasts more than 30 minutes.22 Determining whether lower back pain is inflammatory or mechanical can be challenging because lower back pain is very common in the general population, with 38% experiencing lower back pain for at least 1 day every year.23 However, of all those with chronic lower back pain, IBP represents only approximately 5%.24 Many attempts have been made to classify IBP (Table 1),22,25,26 with the following features considered important in differentiating between IBP and other common causes of back pain:22

(Video) Clinical Recommendations: Managing Axial Spondyloarthritis

  • Age: onset of axSpA after the age of 45 years is exceedingly rare.
  • Duration of pain: non-IBP is often self-limiting.
  • Onset of pain: non-IBP is often acute in onset.
  • Diurnal variation: pain and stiffness in axSpA-related IBP tends to be worse in the second half of the night and early morning.
  • Response to exercise: IBP responds well to exercise, a feature characteristic of many inflammatory conditions.
  • Location: alternating buttock pain can indicate inflammation of sacroiliac joints.22,26

Peripheral Disease

Peripheral arthritis can affect up to half of individuals with axSpA, has a higher prevalence in the Latin American population compared to other geographic regions, tends to be more common in the lower limbs, and is typically oligoarticular.27 Peripheral arthritis in axSpA may affect any joint, but is typically asymmetric. It is important to recognise peripheral arthritis, as its presence may direct management. Conventional synthetic disease-modifying antirheumatic drugs have a role in managing peripheral arthritis, whereas they are ineffective for axial disease.

Entheses are the sites of attachment of tendons or ligaments to bone, and enthesitis (inflammation of entheses) occurs in 44% of individuals with axSpA, with a predominance for lower limbs.27 The heel (Achilles tendon or plantar fascia) is the most common site of enthesitis in axSpA, with most affected individuals having an intermittent course.27 It can be difficult clinically to differentiate between enthesitis and arthritis, due to the anatomic overlap between entheses and joints.28

Dactylitis or ‘sausage digit’ involves inflammation of an entire digit (either a finger or toe), and is caused by flexor tenosynovitis, in combination with soft-tissue oedema.29 Dactylitis can occur in up to 8% of individuals with axSpA,27 although it is more commonly seen in PsA.30 Interestingly, a meta-analysis explored the difference in the prevalence of peripheral manifestations between patients with AS and nr-axSpA and found no significant differences between the two groups.31

Extra-Articular Manifestations

Acute anterior uveitis (AAU), IBD, and psoriasis (PsO) are three conditions that are over-represented in axSpA and are thus considered extra-articular manifestations of the disease.

AAU is the most common extra-articular feature of axSpA, with a reported prevalence of 26–33%.32 AAU associated with axSpA typically presents acutely, often with a 1- to 2-day prodrome, and tends to be unilateral, with circumlimbal hyperaemia, pain, photophobia, and visual impairment, with subsequent attacks often affecting the other eye. AAU more commonly occurs in a HLA-B27-positive patient cohort.33 Visual prognosis in AAU associated with axSpA is excellent, with most individuals regaining full vision within 2 months.34

PsO is another notable feature of axSpA, affecting approximately 10% of individuals.32 This disease feature must be distinguished from a diagnosis of PsA, which may present similarly. Patients with axSpA tend to have more back pain at presentation and score higher on physician score global indices when compared to PsA.35 Interestingly, the presence of PsO in axSpA is an independent risk factor for increased entheseal damage.36

Clinically evident IBD is noted in 6–14% of AS patients,32 with Crohn’s disease occurring more commonly than ulcerative colitis. However, microscopic evidence of IBD was noted in up to 60% of AS patients, suggesting a significant proportion of clinically silent disease.37 Faecal calprotectin is a non-specific marker for gut inflammation. In a 5-year longitudinal study, higher faecal calprotectin levels at baseline were associated with the development of Crohn’s disease, as well as more severe AS disease clinically, but without any relationship to gut symptoms, suggesting that inflammation in the gastrointestinal tract and musculoskeletal system are linked.38

(Video) Axial Spondyloarthritis and Quality of Life


Mortality in axSpA is increased when compared with age- and sex-matched controls.39,40 Some of this excess mortality can be explained as a direct consequence of the disease, such as death because of neurological deficits from vertebral fractures.41 However, comorbid conditions, in particular cardiovascular disease, are shown to be a leading cause of death in axSpA.39,40

A comorbid condition can be defined as any distinct additional clinical entity that has existed or that may occur during the clinical course of an individual who has the index disease under study.

The ASAS-COMOSPA study was a large, multinational, cross-sectional study that outlined the profile of comorbidities occurring in individuals with SpA.42 The most prevalent comorbidity was osteoporosis, affecting 13% of the cohort. Diagnosis of osteoporosis in axSpA using dual-energy X-ray absorptiometry may be difficult in advanced structural disease because of the presence of osteoproliferation, which can falsely increase bone mineral density. Lateral views of the spine are a promising technique for overcoming this.43

Almost 4% of the ASAS-COMOSPA cohort had cardiovascular morbidity,42 with a lower prevalence in axSpA individuals compared with those with peripheral SpA.44 Hypertension and smoking have been shown to be more pervasive in an axSpA population.45

Depression is common in axSpA, with Zhao et al. reporting a prevalence of 15% showing at least moderate depression in a systematic review.46 Obesity is another comorbidity that is shown to be common in axSpA, affecting 15–27% of axSpA cohorts.47,48 Of note, patients with concomitant obesity tend to be less responsive to conventional therapy in axSpA.49

Comorbidities in axSpA are of clinical relevance, as they have been shown to add to the burden of disease. Increasing comorbidity burden is associated with more active disease and worse spinal mobility.47 The presence of comorbidities in SpA adversely affects physical function, work ability, QoL, and increases healthcare expenditure.47,50 Despite this known burden of comorbidities in axSpA, optimal screening for them is poor, with the ASAS-COMOSPA study demonstrating that only half of participants had an adequate assessment of their cardiovascular status, and optimal cancer screening was only performed in 11–44% of participants.42 Less than 20% of individuals with axSpA have an objective assessment of their bone mineral density.47 Treatment of comorbidities is also suboptimal, with less than one-quarter of a Dutch cohort of patients with AS treated for hypertension or hypercholesterolaemia achieving treatment targets.45

FM is a non-inflammatory comorbidity characterised by widespread pain and fatigue, with an estimated one-in-six prevalence in axSpA.51 Patients who met the criteria for FM reported significantly worse disease activity and function, as well as a lower QoL.52 In patient-reported outcomes (PRO), low disease activity or disease remission is less likely to be achieved in patients with FM.53 The presence of FM appears to have a negative impact on response to biologics,54 with shorter retention times.55 For this reason, it is important to screen patients with AxSpA for FM because it may affect patient outcomes.


AxSpA is a complex multifaceted condition, and assessment of outcomes must reflect this. A number of validated outcome measures have been developed in axSpA, which deliver a comprehensive overview, subjectively and objectively, of many different domains of disease. Here, the authors collate scoring systems in axSpA that detail disease activity, patient function, QoL, radiological assessment, as well as objective measurement of enthesitis and dactylitis.

(Video) Axial Spondyloarthritis Defined

Bath Ankylosing Spondylitis Disease Activity Index

The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a validated PRO that measures fatigue, spinal pain, peripheral joints, enthesopathy, and early-morning stiffness severity and duration on a scale of 0–10.56 Scores of 4 or greater suggest active disease, which may require alteration of therapy.57 The benefit of the BASDAI is that it is a simple, patient-focused assessment assessing a wide variety of axSpA features. One of its drawbacks is that objective evidence of inflammation such as C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) is not assessed in the BASDAI. While the BASDAI did not initially include nr-axSpA patients, it has since been suggested that it may also be used in this patient cohort.58

Bath Ankylosing Spondylitis Functional Index

The Bath Ankylosing Spondylitis Functional Index (BASFI) is a patient-reported assessment for everyday tasks, also scored on a scale of 0–10, using either a numerical or a visual analogue.59 This scoring tool is validated, quick and easy to use, and sensitive to changes in the disease.60 Similar to the BASDAI, this tool had initially been validated for AS and not nr-axSpA.

Ankylosing Spondylitis Disease Activity Score

The Ankylosing Spondylitis Disease Activity Score (ASDAS) was developed to include objective measures of inflammation that were not present in the BASDAI. It is closely associated with the Disease Activity score utilised in rheumatoid arthritis. The ASDAS incorporates three questions from the BASDAI (back pain, peripheral pain, and early-morning stiffness), patient global assessment, and acute-phase reactant using either ESR or CRP.61,62 Disease activity is subsequently classified into inactive, moderate, high, and very high disease activity states.63 The ASDAS has demonstrated validity and is more sensitive to treatment than previous scoring metrics.64 A notable disadvantage of the ASDAS is CRP or ESR may not be available on clinic days. Also, a raised CRP or ESR may not always reflect disease activity.

Health Assessment Questionnaire

The Health Assessment Questionnaire (HAQ) is a PRO questionnaire, which initially focused on pain, disability, medication effects, costs, and mortality. Answers are assessed from 0–3, where 3 indicates more severe disability.65

Ankylosing Spondylitis Quality of Life

The Ankylosing Spondylitis Quality of Life (ASQoL) questionnaire is comprised of 18 questions that aim to accurately assess QoL in patients with AS.66 It may also be used in nr-axSpA. Each question is yes/no, with each ‘yes’ scoring one point. The points are summed, giving a total score between 0 and 18, with a higher score signifying a worse QoL. Difficulties with the AS QoL include failure of a yes/no answering system to fully encapsulate a patient’s sense of wellbeing.

Bath Ankylosing Spondylitis Metrology Index

The Bath Ankylosing Spondylitis Metrology Index (BASMI) differs from previous scoring systems in that it assesses objective clinical measurements rather than PRO. BASMI assesses spinal mobility on a scale of 0–10.67 The composite score measures cervical rotation, wall-to-tragus distance, lateral flexion, modified Schober’s test, and intermalleolar distance. Higher scores reflect more significant restriction. It is a quick and reproducible assessment that demonstrates high sensitivity.

Modified Stoke Ankylosing Spondylitis Spinal Score

The Modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) was developed to assess radiographic changes in AS.68 It uses lateral spinal X-rays to quantify radiological damage on the anterior aspect of the spine from the lower border of C2 to the upper border of T1, plus the lower border of T12, all five lumbar vertebrae, and upper sacrum. This scale scores each vertebra border on a 0–3 scale: 0 is normal; 1 shows sclerosis erosions or squaring; 2 is for obvious syndesmophyte formation; and 3 shows total bridging syndesmophyte formation. A summed score of 0 indicates a normal spine, and 72 a completely ankylosed, or ‘bamboo’, spine.

Maastricht Ankylosing Spondylitis Enthesitis Score

The Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) is a scoring system of enthesopathy in patients with spondyloarthritis. Thirteen sites are assessed for discomfort on clinical examination in binary terms of tender or non-tender.69 This scoring system is more user-friendly than previous enthesitis measurements such as the Mander Enthesis Index (MEI). High enthesitis scores correlate well with high disease activity scores.

(Video) Axial Spondyloarthritis Defined

Leeds Dactylitis Instrument

The Leeds Dactylitis Instrument (LDI) is a validated clinical measurement of dactylitis. Dactylitis was defined as an increase of 10% or more of the size of the contralateral unaffected digit.70 Measurement of degree of tenderness is also assessed clinically in order to complete the score. High scores are associated with worse dactylitis.


Although a detailed overview of treatment is beyond the scope of this narrative review, the authors here outline the general principles of management of axSpA, based on existing recommendations(Figure 1).58,71 Briefly, the management of axSpA may be classified into non-pharmacological and pharmacological treatment, and treatment should be tailored according to the manifestations of the disease, the severity of symptoms, the clinical status of the patient, and the expectations and wishes of the patient.58 The importance of regular exercise and avoiding smoking must be emphasised to each patient, regardless of other treatment modalities. If the patient is symptomatic, regular NSAIDs are typically the first line of pharmacological treatment. If there is insufficient response with NSAIDs, patients with predominantly axial disease should be assessed for biologic disease-modifying anti-rheumatic drugs. Currently, anti-TNFs, anti-IL-17, and JAK inhibitors are licensed for axSpA treatment (Table 2).


For too long, patients were often excluded from decisions regarding management of their condition. This has been addressed with the publication of the European League Against Rheumatism (EULAR) recommendations for patient education in inflammatory arthritis.72 Shared decision-making between the patient and rheumatologist is now an overarching principle in the recommended management of axSpA.58

To ensure that the patient can partake in all elements of this shared decision, education is key and refers to all activities that ensure an individual is well-informed about their condition, from education about treatment options to general health education and health promotion.72 Patient education, which can range from patient information leaflets to structured educational programmes, has been shown to increase adherence to treatment and promote patient self-management.73

The rheumatology nurse plays a key role in educating patients, with the updated 2018 EULAR guidelines recognising the importance of rheumatology-trained nurses in providing needs-based education to individuals affected with chronic inflammatory arthritis.74 The Educational Needs Assessment Tool (ENAT) is one instrument that can accurately assess an individual’s educational need and has been validated in many rheumatic conditions, including AS.75 Using the results of the ENAT to guide the education of a patient can lead to improved outcomes.76 However, the ENAT alone is not sufficient, and the focus should be placed on individualised patient education, which should be tailored according to their needs.74

One area where patient education is particularly key is in promoting the role of physical exercise in axSpA. Although the most effective exercise protocol in axSpA has not been clearly established, physical exercise is shown to improve disease activity and physical function in individuals with SpA. Despite this, physical activity is lower in adults with axSpA compared to the general population, with higher disease activity levels in those who are less physically active.77 Many individuals with axSpA lack motivation to partake in physical activity, even when aware of the benefits.78 Additionally, many individuals with rheumatic conditions are unaware of physical activity guidelines.79 A 3-month behavioural intervention in axSpA that incorporated motivational interviewing techniques resulted in better QoL, spinal mobility, and physical activity levels in patients with axSpA compared to a control group, which was sustained at Month 6.80 This highlights the positive role that patient education can play in the management of axSpA.


In summary, axSpA is a chronic inflammatory condition, with both spinal and extraspinal manifestations. Recognition of IBP can be challenging, but the most recent ASAS IBP criteria have increased the sensitivity and specificity of the classification criteria. HLA-B27 is thought to play a significant role in the pathophysiology, but more research is needed to fully elucidate the pathways. Awareness of extraspinal manifestations of axSpAis is low, as shown by the infrequent screening that occurs. Regularly assessing multiple different disease outcomes with validated tools is an important part of managing axSpA, and assessing the effect of treatment. Enhancing patient involvement in their own management is also key.

(Video) Diagnostic Approach and Management of Spondyloarthritis by Prof. Suzan Attar


What is the best treatment for axial spondyloarthritis? ›

Treatment for axSpA usually starts with nonsteroidal anti-inflammatory drugs (NSAIDs), physical therapy and exercise. As long as your disease isn't too advanced, NSAIDs and regular movement are usually enough to keep things under control.

What are the symptoms of axial spondyloarthritis? ›

The most common symptom of axial spondyloarthritis (axSpA) is pain in the lower back. Some people also have pain, stiffness, and limited mobility outside the spine, such as in the hips, knees, and heels.

What is axial spondyloarthritis? ›

Axial spondyloarthritis (axSpA) is a type of arthritis. It mostly causes pain and swelling in the spine and the joints that connect the bottom of the spine to the pelvis (sacroiliac joint). Other joints can be affected as well.

How do you treat spondyloarthritis naturally? ›

These 10 natural therapies may help relieve symptoms:
  1. Stretching. Stretching helps build flexibility and may reduce pain. ...
  2. Heat therapy. To reduce stiffness and pain, apply a hot-water bottle or heating pad to the affected area. ...
  3. Cold therapy. ...
  4. Acupuncture. ...
  5. Massage therapy. ...
  6. Movement. ...
  7. Exercise. ...
  8. Alexander Technique.

Who treats axial spondyloarthritis? ›

Diagnosis of Non-Radiographic Axial Spondyloarthritis

A rheumatologist will generally diagnose and treat nr-axSpA. Rheumatologists have special training in diagnosing and treating disorders that affect the joints, tendons, ligaments, connective tissue, muscles, and bones.

What blood test shows axial spondyloarthritis? ›

Blood test to look at inflammatory markers. If you have inflammation in a part of your body then extra protein can be released from the site of inflammation and circulates in the bloodstream. The erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and plasma viscosity (PV) blood tests are commonly used.

Does axial spondyloarthritis show up on MRI? ›

MRI of the sacroiliac joints (SIJs) is recognised as key imaging biomarker of axial spondyloarthritis (SpA), especially for recognition of emerging inflammation in the early phase of the disease.

How serious is axial spondyloarthritis? ›

Up to 6 percent of people with chronic back pain will ultimately receive a diagnosis of axial spondyloarthritis, but the disease often takes as long as 10 years to be diagnosed — a delay that can hugely impact your quality of life and lead to disability, missed time at work, and increased health care costs.

How do you treat axial pain? ›

Treatment of Axial Low Back Pain

A short period of rest (e.g. one or two days) Physical therapy and active exercise and stretching. Ice and/or heat application for activity related pain relief. Appropriate medications for pain relief.

What exercises reduce spondylitis? ›

Press Up to Stretch Your Spine

Ankylosing spondylitis (AS) can shorten the spine and muscles in your back. Stretch with this move to help "rounded" back and back pain. Lie on your stomach with your legs behind you. Slowly prop yourself up on your elbows so your chest is off the ground.

What is the latest treatment for ankylosing spondylitis? ›

(2021) Adalimumab therapy restores the gut microbiota in patients with ankylosing spondylitis.

What is the difference between axial spondyloarthritis and ankylosing spondylitis? ›

To clear things up, Ankylosing Spondylitis (AS) is actually the same as Axial Spondyloarthritis (AxSpA), but only one of the 2 subgroups of AxSpA. AS is known as radiographic AxSpA, whereas the other subgroup is known as non-radiographic.

Can axial spondyloarthritis go away? ›

There is no cure for axial spondyloarthritis. However, symptoms caused by this condition are treated with medications, physical therapy, home remedies, lifestyle changes, and, in rare cases, surgery.

Is axial spondyloarthritis inflammatory? ›

Axial spondyloarthritis (axial SpA) is an inflammatory arthritis where the main symptom is back pain. Where changes to the sacroiliac joints or the spine can be seen on x-ray. Where x-ray changes are not present but inflammation is visible on MRI or you have symptoms.

What happens if you don't treat spondyloarthritis? ›

You might end up with a deformed spine

As the disease progresses, moving your spine gets increasingly difficult. The less you move your spine, the stiffer it can get. In the most severe cases, chronic inflammation causes the formation of extra bone between your vertebrae.

What foods help spondyloarthritis? ›

For spondyloarthritis in general, following a mostly plant-based diet again is recommended; plenty of vegetables, fruit, whole grains and healthy fats from nuts, seeds, avocado, and fish. Again, I will often recommend avoiding highly processed foods, particularly those high in saturated fats, sugar or salt.

Is massage good for spondylitis? ›

Many people with spondylitis find therapeutic massage very helpful. If done carefully, it can be a beneficial tool for pain relief and stress reduction.

Do steroids help axial spondyloarthritis? ›

medwireNews: Treatment with oral prednisolone on a step-down regimen may reduce disease activity in people with axial spondyloarthritis (axSpA) but has minimal impact on other outcomes such as functional improvement, Indian researchers report.

What is first line treatment for ankylosing spondylitis? ›

Nonsteroidal anti-inflammatory drugs (NSAIDs) — such as naproxen (Aleve, Naprosyn, others) and ibuprofen (Advil, Motrin IB, others) — are the medications doctors most commonly use to treat ankylosing spondylitis.

What is the prognosis for spondyloarthritis? ›

The outlook for AS is highly variable. For some people the condition improves after an initial period of inflammation, whereas for others it can get progressively worse over time. Some people with AS are able to remain fully independent or minimally disabled in the long-term.

Is axial spondyloarthritis a chronic illness? ›

Axial Spondyloarthritis - also known as axSpA or axial SpA - is a painful, chronic arthritis that mainly affects the joints of the spine. It can also affect other joints in the body, as well as tendons and ligaments.

Is axial spondyloarthritis a rare disease? ›

Myth: Axial spondyloarthritis is rare

A disease is considered “rare” if it affects fewer than 200,000 people. According to a widely cited study that aimed to establish the national prevalence of spondylarthritis in the U.S., about 2.7 million Americans or more are affected by axSpA.

How do people live with spondyloarthritis? ›

Physical. Working on various lifestyle factors can help relieve some of the pain or discomfort associated with axial spondyloarthritis. These include engaging in appropriate, low-impact exercises, eating foods less likely to cause inflammation, getting quality sleep, and not smoking.

Does axial spondyloarthritis cause fatigue? ›

Introduction: Fatigue is frequent in long-standing axial spondyloarthritis (axSpA); its frequency in early axSpA and its causes are unclear.

Does axial spondyloarthritis come and go? ›

The symptoms of ankylosing spondylitis (AS) usually develop slowly over several months or years. The symptoms may come and go, and improve or get worse, over many years. AS usually first starts to develop between 20 to 30 years of age.

Can axial spondyloarthritis go into remission? ›

Remission is unlikely in non-radiographic axial spondyloarthritis without biologic therapy. Adding certolizumab to background therapy can lead to significant improvements in disease activity compared to placebo, researchers find. In a recent article published in Arthritis & Rheumatology,Dr.

Can spondyloarthritis cause nerve damage? ›

The condition causes bone growth, which leads to pressure and swelling at the end of the spinal cord. This swelling can compact the nerves in the lower back and cause symptoms such as: pain and numbness. stinging or tingling sensations in the legs.

What does axial spondyloarthritis pain feel like? ›

Back and/or neck pain. Spinal stiffness/reduced range of motion in the back and neck (severe forms of ankylosing spondylitis can lead to total loss of spinal flexibility) Spine pain that started gradually and has persisted more than 3 months. Pain that worsens after rest and eases with activity.

What does axial spondyloarthritis feel like? ›

Non-radiographic axial spondyloarthritis (nr-axSpA) is a type of arthritis in your spine. It causes inflammation, which leads to symptoms like redness, swelling, heat, stiffness, and pain. The condition affects the joints and the entheses -- tissues that connect bones to ligaments or tendons.

How can I reduce inflammation in my spine? ›

Ankylosing Spondylitis: 9 Ways to Reduce Inflammation
  1. Take your medications as directed. ...
  2. If you smoke tobacco, quit. ...
  3. Include good fats in your diet. ...
  4. Avoid high-heat cooking. ...
  5. Try using anti-inflammatory spices. ...
  6. Do low-impact extension exercises. ...
  7. Use heat or cold therapy. ...
  8. Get a good night's sleep.
28 May 2020

What causes axial pain? ›

What are the causes of axial neck pain? There are a variety of anatomical structures that can cause axial neck pain. Injury to the muscles and ligaments supporting the skull and cervical spine is a common cause of pain and can be precipitated by poor posture, ergonomics, or trauma.

What is the best biologic for ankylosing spondylitis? ›

Two are FDA-approved for ankylosing spondylitis: ixekizumab (Taltz) and secukinumab (Cosentyx). They target different cytokines than the TNF inhibitors.
There are five approved for ankylosing spondylitis:
  • Adalimumab (Humira)
  • Certolizumab (Cimzia)
  • Entanercept (Enbrel)
  • Golimumab (Simponi)
  • Infliximab (Remicade)
10 Oct 2022

What is the fastest way to cure spondylitis? ›

There's no cure for ankylosing spondylitis (AS), but treatment is available to help relieve the symptoms. Treatment can also help delay or prevent the process of the spine joining up (fusing) and stiffening. In most cases treatment involves a combination of: exercise.

Which pillow is best for spondylosis? ›

MALVOLIO Premium Universal Contoured Cervical Pillow | Best for - Cervical Spondylitis, Neck Sprains/Stiff Neck & All Type Pain Reduction (Beige, Free Size)

Which injection is best for ankylosing spondylitis? ›

SIMPONI® is the first and only self-injectable biologic treatment for adults with active ankylosing spondylitis that requires just one injection each month. Your results may vary. Once you and your doctor are comfortable with the self-injection process, you will inject SIMPONI® under the skin, just once a month.

Can spondylitis be cured without surgery? ›

The majority of spondylosis patients respond well to nonsurgical forms of treatment, such as: Medication: Your doctor may prescribe nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics (pain killers), and/or muscle relaxants. Physical therapy: If needed, your doctor will refer you to a physical therapist.

What triggers ankylosing spondylitis? ›

Ankylosing spondylitis has no known specific cause, though genetic factors seem to be involved. In particular, people who have a gene called HLA-B27 are at a greatly increased risk of developing ankylosing spondylitis. However, only some people with the gene develop the condition.

Is spondyloarthritis the same AS arthritis? ›

Spondyloarthritis is a type of arthritis that attacks the spine and, in some people, the joints of the arms and legs. It can also involve the skin, intestines and eyes. The main symptom (what you feel) in most patients is low back pain.

Is axial spondyloarthritis the same AS rheumatoid arthritis? ›

When you think of inflammatory arthritis like rheumatoid arthritis, you often think of it affecting the small joints like the hands and feet. Non-radiographic axial spondyloarthritis (nr-AxSpA) is a different kind of inflammatory arthritis.

What is ankylosing spondylitis mistaken for? ›

Reactive arthritis usually targets your knees and the joints of your ankles and feet, but — similar to AS — you may also have pain in your heels, low back, or buttocks. Many people who have reactive arthritis also develop eye inflammation.

How fast does spondyloarthritis progress? ›

Not every patient with non-radiographic axial spondyloarthritis will progress to AS — different studies have found progression rates from nr-axSpA to AS of 5 percent to 30 percent over as many as 30 years. When the disease does progress, it doesn't do so predictably.

Does spondylitis show up on xray? ›

X-rays are the gold standard imaging test for diagnosing ankylosing spondylitis. Your doctor will likely diagnose you with ankylosing spondylitis if your X-rays show signs of inflammation or fusing of your vertebrae and you also have typical symptoms.

Can a chiropractor help with spondyloarthritis? ›

Chiropractic care is not usually recommended as an ankylosing spondylitis treatment. Spinal adjustments done by a chiropractor could, unintentionally, cause a fracture or dislocation in the neck or spine, given the way the bones are fused together. This is a particular worry when it comes to the neck.

What triggers axial spondyloarthritis? ›

Axial spondyloarthritis is an autoimmune disorder that typically develops before a person reaches middle age. Early symptoms include back pain and stiffness. The exact cause of this condition is not known, but risk factors include genetics, other medical conditions, and lifestyle factors, such as smoking.

Can axial spondyloarthritis cause muscle spasms? ›

Pain can be caused by your axial SpA for a number of different reasons, including: Inflammation around the joints or muscles. Shortening or tightening of muscles or tendons. Protective muscle spasms.

What are the 4 body areas affected by ankylosing spondylitis? ›

It can affect peripheral joints (the hands, knees, elbows, shoulders, and feet) as well as the spine. The spinal involvement occurs in 25 to 70 percent of people with PsA.

What bacteria causes ankylosing spondylitis? ›

Ankylosing spondylitis is caused by Klebsiella.

What exercise is best for ankylosing spondylitis? ›

Optimal Activities to Help Manage Ankylosing Spondylitis

Low- or no-impact activities, such as yoga, tai chi, swimming, walking, or cycling are best for people with joint pain. Exercises for AS may be done at home or in a gym, or in a group or individual physical therapy program.

What is the best treatment for spondylosis? ›

In most cases, the symptoms of cervical spondylosis can be relieved using a combination of: medication – such as non-steroidal anti-inflammatory drugs (NSAIDs), including ibuprofen. exercise – such as swimming and walking. self care techniques – such as supporting your neck with a firm pillow at night.

What should be avoided in ankylosing spondylitis? ›

High fat foods

The Arthritis Foundation recommends limiting types of fat that cause inflammation, including saturated fats and omega-6 fatty acids. Foods that contain saturated fats include: pizza. red meat.

What triggers spondyloarthritis? ›

The specific causes of most types of spondyloarthritis are unknown, although medical experts have found genetic factors. People who have a gene known as HLA-B27 are at a higher risk of developing ankylosing spondylitis, enteropathic arthritis, psoriatic arthritis, and reactive arthritis.

Can spondyloarthritis affect the heart? ›

Although axSpA primarily impacts the lower back and the joints that connect the spine to the pelvis (sacroiliac joints), it may also cause damage elsewhere in the body, including your heart and blood vessels.

What is the most serious complication of spondylosis? ›

Spondylosis can lead to spinal stenosis, which is a narrowing of the spinal canal. As a result, the spinal cord and/or spinal nerve roots can become compressed (pinched). For example, the cervical spinal cord can be affected by compression from spondylosis. This is called cervical spondylotic myelopathy.


1. Medical Management of Spondyloarthritis Presented by Liron Caplan, MD PhD
2. CAPES: Juvenile Spondyloarthritis (JSpA) and Juvenile Psoriatic Arthritis (JPsA) Clinician Webinar
3. How TENS machines can help manage your axial spondyloarthritis pain
(National Axial Spondyloarthritis Society)
4. ABCs of EIMs in IBD (Graphic)
(Cleveland Clinic)
5. 5/27/16: Delayed Recognition of Spondyloarthritis: Diagnostic Challenges & Opportunities
(UW Department of Medicine)
6. IL-17 Inhibitors in Nonradiographic Axial Spondyloarthritis
(PeerView CME)
Top Articles
Latest Posts
Article information

Author: Duncan Muller

Last Updated: 01/03/2023

Views: 6130

Rating: 4.9 / 5 (79 voted)

Reviews: 86% of readers found this page helpful

Author information

Name: Duncan Muller

Birthday: 1997-01-13

Address: Apt. 505 914 Phillip Crossroad, O'Konborough, NV 62411

Phone: +8555305800947

Job: Construction Agent

Hobby: Shopping, Table tennis, Snowboarding, Rafting, Motor sports, Homebrewing, Taxidermy

Introduction: My name is Duncan Muller, I am a enchanting, good, gentle, modern, tasty, nice, elegant person who loves writing and wants to share my knowledge and understanding with you.